Through lifestyle modifications, ADORE will assess the progress of patients based on parameters like reduction in blood sugar levels and weight, among others
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
In clinical trials, treatment proved more effective than other therapies evaluated
India has the second-largest number of adults with diabetes globally, after China
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
Subscribe To Our Newsletter & Stay Updated
